CStone Pharma climbs 6% on Kimia Therapeutics collaborationMarket Movers·Nov 18, 2026 at 05:46 AM02616+7.97%
Weekly Recap | CSTONE PHARMA-B -3.79%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 05:24 AM02616+7.97%
Weekly Recap | CSTONE PHARMA-B +7.98%, Kimia clinical collaboration announcedWeekly Review·Nov 7, 2026 at 05:54 AM02616+7.97%
CStone Pharma climbs 6% as CS2009 shows 87.5% response rate in lung cancerMarket Movers·Oct 28, 2026 at 03:06 AM02616+7.97%
CStone's CS2009 shows 87.5% response rate in first-line PD-L1-high lung cancerPUBT·Oct 26, 2026 at 08:22 AM02616+7.97%
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activitybiopharmadive·Oct 26, 2026 at 05:25 AM02616+7.97%
CStone Pharma climbs 7% as CS2009 shows 87.5% lung cancer responseMarket Movers·Oct 26, 2026 at 01:30 AM02616+7.97%
CStone reports 87.5% response rate for CS2009 in first-line PD-L1-high lung cancerPUBT·Oct 25, 2026 at 10:10 AM02616+7.97%
Weekly Recap | CSTONE PHARMA-B -2.01%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 05:22 AM02616+7.97%